Juvenal Tobin W sold $207K of CSTL
Juvenal Tobin W (Chief Commercial Officer) sold 6,116 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $33.77 ($32.67–$35.04, $0.21M total) across 2 trades over 2026-11-09 to 2026-11-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the insider's ownership but is modest relative to total shares outstanding, likely causing limited price movement.
Market read
A small insider sell filed via a 10b5‑1 plan; modest relevance for short‑term traders, more informational for long‑term holders.
What to watch
Potential upcoming clinical milestones or financing needs that prompted the 10b5‑1 plan are not disclosed.
Background
SEC Form 4 filings provide the first public disclosure of insider transactions, offering transparency into insider holdings.
Ticker impact
Chief Commercial Officer sold 6,116 shares for $206K via a 10b5‑1 plan, reducing his stake to 32,737 shares.
likely modest pressure as the market prices in the insider sell
The transaction size is modest for a micro‑cap and executed under a pre‑arranged plan, limiting informational content.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine and unlikely to shift sector sentiment.
No regional effect; the filing is company‑specific.
Limited global relevance; only relevant to investors tracking CSTL.
Counterpoint
The sale could be a routine liquidity event, not a negative signal; the remaining stake remains sizable.
Key entities
- CompanyCastle Biosciences Inc
Biotech firm developing diagnostic tests; ticker CSTL.
- PersonJuvenal Tobin W
Chief Commercial Officer of Castle Biosciences, reporting the insider sale.
